Dmitry Balyasny’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-5,288,097
| Closed | -$1.31M | – | 3451 |
|
|
2026
Q1 | $1.31M | Buy |
+5,288,097
| New | +$2.1M | ﹤0.01% | 1966 |
|
|
2025
Q1 | – | Sell |
-136,687
| Closed | -$139K | – | 3233 |
|
|
2024
Q4 | $139K | Buy |
+136,687
| New | +$250K | ﹤0.01% | 2573 |
|
|
2024
Q3 | – | Sell |
-31,773
| Closed | -$11.4K | – | 3121 |
|
|
2024
Q2 | $11.4K | Buy |
+31,773
| New | +$17.2K | ﹤0.01% | 2490 |
|
|
2023
Q1 | – | Sell |
-21,355
| Closed | -$67.1K | – | 3098 |
|
|
2022
Q4 | $67.1K | Buy |
+21,355
| New | +$82.9K | ﹤0.01% | 2308 |
|
|
2022
Q3 | – | Sell |
-25,900
| Closed | -$107K | – | 3223 |
|
|
2022
Q2 | $107K | Buy |
25,900
+7,753
| +43% | +$33.5K | ﹤0.01% | 2273 |
|
|
2022
Q1 | $105K | Buy |
+18,147
| New | +$108K | ﹤0.01% | 2133 |
|
|
2020
Q2 | – | Sell |
-92,994
| Closed | -$592K | – | 1455 |
|
|
2020
Q1 | $592K | Buy |
92,994
+51,863
| +126% | +$385K | 0.01% | 867 |
|
|
2019
Q4 | $344K | Buy |
+41,131
| New | +$378K | ﹤0.01% | 1048 |
|
|
2019
Q3 | – | Sell |
-17,264
| Closed | -$186K | – | 1532 |
|
|
2019
Q2 | $186K | Buy |
+17,264
| New | +$184K | ﹤0.01% | 1403 |
|
|
2019
Q1 | – | Sell |
-25,806
| Closed | -$296K | – | 1630 |
|
|
2018
Q4 | $296K | Buy |
+25,806
| New | +$321K | ﹤0.01% | 1233 |
|
|
2017
Q4 | – | Sell |
-14,451
| Closed | -$217K | – | 2273 |
|
|
2017
Q3 | $217K | Sell |
14,451
-337,249
| -96% | -$3.73M | ﹤0.01% | 1672 |
|
|
2017
Q2 | $3.1M | Buy |
+351,700
| New | +$2.26M | 0.01% | 857 |
|
|
2016
Q2 | – | Sell |
-163,697
| Closed | -$990K | – | 1414 |
|
|
2016
Q1 | $990K | Sell |
163,697
-1,441,193
| -90% | -$8.65M | 0.01% | 773 |
|
|
2015
Q4 | $14.7M | Buy |
1,604,890
+1,527,638
| +1,977% | +$11.8M | 0.1% | 267 |
|
|
2015
Q3 | $436K | Buy |
+77,252
| New | +$637K | ﹤0.01% | 836 |
|
|
2015
Q1 | – | Sell |
-740,857
| Closed | -$11.3M | – | 1058 |
|
|
2014
Q4 | $11.3M | Buy |
740,857
+560,857
| +312% | +$6.81M | 0.1% | 274 |
|
|
2014
Q3 | $1.94M | Buy |
+180,000
| New | +$2.35M | 0.02% | 610 |
|
|
2014
Q2 | – | Sell |
-276,600
| Closed | -$5M | – | 761 |
|
|
2014
Q1 | $5M | Buy |
276,600
+77,135
| +39% | +$1.49M | 0.06% | 368 |
|
|
2013
Q4 | $2.77M | Buy |
+199,465
| New | +$2.3M | 0.04% | 379 |
|
Other funds holding SGMO
NAMI
AIM
FTUS
HIG
Dmitry Balyasny's SGMO Position: Q2 2026 in Review
Dmitry Balyasny sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 5,288,097 shares — an estimated $1.31M sold.
Dmitry Balyasny first reported a position in SGMO in Q4 2013 and held it in 19 quarters. The position peaked at $14.7M in Q4 2015. 6 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.
- Dmitry Balyasny reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
- Dmitry Balyasny sold 5,288,097 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $1.31M.
- Dmitry Balyasny first reported a position in SANGAMO THERAPEUTICS INC in Q4 2013 and held it in 19 quarters.
- Dmitry Balyasny's SANGAMO THERAPEUTICS INC position peaked at $14.7M in Q4 2015.
- 6 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.